What one share of BridgeBio Pharma holds
BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs.
BridgeBio Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.68 |
|---|---|
| Profit | −$3.57 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.24 |
| Cash and investments | $3.47 |
| Debt | $13.58 |
| Book value | −$12.88 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$1.00 | $0.02 | −$1.34 | — | $2.81 |
| 2018 | — | −$2.12 | $0.04 | −$2.25 | — | $3.42 |
| 2019 | $0.39 | −$2.48 | $0.03 | −$2.44 | — | $3.30 |
| 2020 | $0.07 | −$3.80 | $0.06 | −$3.45 | — | $0.47 |
| 2021 | $0.48 | −$3.90 | $0.09 | −$3.54 | — | −$5.91 |
| 2022 | $0.53 | −$3.26 | $0.03 | −$2.88 | — | −$8.33 |
| 2023 | $0.06 | −$3.95 | $0.01 | −$3.25 | — | −$7.73 |
| 2024 | $1.19 | −$2.88 | $0.01 | −$2.80 | — | −$7.72 |
| 2025 | $2.62 | −$3.79 | $0.01 | −$2.33 | — | −$10.71 |
Common questions about BridgeBio Pharma
How much does one share of BridgeBio Pharma earn?
Over the last 12 months, BridgeBio Pharma lost $3.57 for each share on $3.68 of sales.
Does BridgeBio Pharma pay a dividend?
BridgeBio Pharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is BridgeBio Pharma’s book value per share?
BridgeBio Pharma’s book value is negative (−$12.88 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of BridgeBio Pharma have?
Each share of BridgeBio Pharma has $3.47 of cash and investments and $13.58 of debt, as of June 30, 2026.
What is BridgeBio Pharma’s free cash flow per share?
−$2.24 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has BridgeBio Pharma bought back shares?
BridgeBio Pharma’s share count rose about 526% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.